BEAM 10-Q report for 2025-09-30

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States.

BEAM 10-Q report for 2025-09-30 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39208 Beam Therapeutics Inc. (Exact name of Registrant as specified in its Charter) Delaware 81-5238376 ( State or other jurisdiction of incorporation or organization ) ( I.R.S. Employer Identification No. ) 238 Main Street Cambridge , MA 02142 ( Address of principal executive offices ) ( Zip Code ) Registrant’s telephone number, including area code: ( 857 ) 327-8775 Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.01 per share BEAM Nasdaq Global Select Market Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ NO ☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ NO ☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. Large accelerated filer ☒ Accelerated filer ☐ Non-accelerated filer ☐ Smaller reporting company ☐ Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). YES ☐ NO ☒ The number of shares of registrant’s common stock outstanding as o f October 28, 2025 was 101,474,944 . CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. Such forward-looking statements reflect, among other things: • our current expectations and anticipated results of operations; • our expectations regarding the initiation, timing, progress and results of our clinical trials, including our Phase 1/2 clinical trial designed to assess the safety and efficacy of BEAM-101 for the treatment of sickle cell disease, our Phase 1/2 clinical trial designed to assess the safety and efficacy of BEAM-302 for the treatment of alpha-1 antitrypsin deficiency, our Phase 1/2 clinical trial designed to assess the safety and efficacy of BEAM-301 for the treatment of glycogen storage disease type 1a, and our Phase 1 healthy volunteer clinical trial of BEAM-103; • our expectations regarding the initiation, timing, progress and results of our research and development programs and preclinical studies; • our ability to develop and maintain a sustainable portfolio of product candidates; • our ability to develop life-long, curative, precision genetic medicines for patients through base editing; • our ability to create a hub for partnering with other companies; • our plans for preclinical studies for product candidates in our pipeline; • our ability to advance any product candidates that we may develop and successfully complete any clinical trials or preclinical studies, including the manufacture of any such product candidates; • our ability to pursue a broad suite of clinically validated delivery modalities; • our expectations regarding our ability to generate additional novel lipid nanoparticles that we believe could accelerate novel nonviral delivery of gene editing or other nucleic acid payloads to tissues beyond the liver and our ability to expand the reach of our programs; • the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and technology; • developments related to our competitors and our industry; • the expected timing, progress and success of our collaborations with third parties, Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 22 Item 3. Quantitative and Qualitative Disclosures About Market Risk 36 Item 4. Controls and Procedures 37 PART II Other Information 38 Item 1. Legal Proceedings 38 Item 1A. Risk Factors 38 Item 5. Other Information 42 Item 6. Exhibits 43 Signatures 44 PART I. FINANCI AL INFORMATION Item 1. Financial St atements (Unaudited) Beam Therapeutics Inc. Condensed Consolidated Ba lance Sheets ( Unaudited ) (in thousands, except share and per share amounts) September 30, 2025 December 31, 2024 Assets Current assets: Cash and cash equivalents $ 267,960 $ 281,967 Marketable securities 807,010 568,773 Prepaid expenses and other current assets 23,577 27,409 Total current assets 1,098,547 878,149 Property and equipment, net 108,290 111,412 Restricted cash 6,656 8,144 Operating lease right-of-use assets 96,995 104,865 Other assets 593 1,254 Total assets $ 1,311,081 $ 1,103,824 Liabilities and stockholders’ equity Current liabilities: Accounts payable $ 9,545 $ 3,871 Accrued expenses and other current liabilities 42,314 47,468 Current portion of derivative liabilities 6,500 8,400 Current portion of deferred revenue 110,320 108,858 Current portion of lease liability 12,688 13,469 Current portion of consideration liabilities 1,192 — Total current liabilities 182,559 182,066 Long-term lease liability 138,732 147,956 Long-term portion of contingent consideration liabilities 6,708 1,131 Long-term portion of deferred revenue 10,160 33,218 Long-term portion of derivative liabilities 6,654 5,404 Other liabilities 266 504 Total liabilities 345,079 370,279 Commitments and contingencies  (See Note 7, License agreements and Note 8,  Collaboration and license agreements ) Stockholders’ equity: Preferred stock, $ 0.01  par value; 25,000,000  shares authorized, and no  shares issued or outstanding at September 30, 2025 and December 31, 2024, respectively — — Common stock, $ 0.01  par value; 250,000,000  shares authorized, 101,359,765  and 83,633,069  issued and outstanding at September 30, 2025 and December 31, 2024, respectively 1,014 836 Additional paid-in capital 2,855,118 2,298,661 Accumulated other comprehensive (loss) income 790 679 Accumulated deficit ( 1,890,920 ) ( 1,566,631 ) Total stockholders’ equity 966,002 733,545 Total liabilities and stockholders’ equity $ 1,311,081 $ 1,103,824 The accompanying notes are an integral part of these condensed consolidated financial statements. 1 Beam Therapeutics Inc. Condensed Consolidated Statements of Operati ons and Other Comprehensive Loss ( Unaudited ) (in thousands, except share and per share amounts) Three Months Ended September 30, Nine Months Ended September 30, 2025 2024 2025 2024 License and collaboration revenue $ 9,698 $ 14,269 $ 25,634 $ 33,451 Operating expenses: Research and development 109,769 94,258 310,343 266,117 General and administrative 26,740 26,515 81,539 82,865 Total operating expenses 136,509 120,773 391,882 348,982 Loss from operations ( 126,811 ) ( 106,504 ) ( 366,248 ) ( 315,531 ) Other income (expense): Change in fair value of derivative liabilities ( 2,757 ) ( 200 ) 650 2,400 Change in fair value of non-controlling equity investments 4,937 ( 2,064 ) 7,271 ( 13,003 ) Change in fair value of contingent consideration liabilities 1,000 ( 27 ) 945 1,619 Interest and other income (expense), net 10,903 12,127 33,093 38,166 Total other income (expense) 14,083 9,836 41,959 29,182 Net loss before income taxes ( 112,728 ) ( 96,668 ) ( 324,289 ) ( 286,349 ) Provision for income taxes — — — ( 39 ) Net loss $ ( 112,728 ) $ ( 96,668 ) $ ( 324,289 ) $ ( 286,388 ) Unrealized gain (loss) on marketable securities 780 2,869 111 1,155 Comprehensive loss $ ( 111,948 ) $ ( 93,799 ) $ ( 324,178 ) $ ( 285,233 ) Net loss per common share, basic and diluted $ ( 1.10 ) $ ( 1.17 ) $ ( 3.32 ) $ ( 3.49 ) Weighted-average common shares outstanding, basic and diluted 102,570,801 82,410,095 97,567,229 82,141,383 The accompanying notes are an integral part of these condensed consolidated financial statements. 2 Beam Therapeutics Inc. Condensed Consolidated Statements of Stockholders’ Equity ( Unaudited ) (in thousands, except share amounts) Common Stock Additional Paid-in Accumulated Other Comprehensive Accumulated Total Stockholders’ Shares Amount Capital Income (Loss) Deficit Equity Balance at December 31, 2023 81,632,496 $ 816 $ 2,169,798 $ 604 $ ( 1,189,889 ) $ 981,329 Purchase of common stock under ESPP 76,461 1 1,397 — — 1,398 Vesting of restricted common stock 420,579 4 ( 4 ) — — — Stock-based compensation — — 29,281 — — 29,281 Exercise of common stock options 151,291 2 1,674 — — 1,676 Other comprehensive income (loss) — — — ( 1,525 ) — ( 1,525 ) Net loss — — — — ( 98,669 ) ( 98,669 ) Balance at March 31, 2024 82,280,827 $ 823 $ 2,202,146 $ ( 921 ) $ ( 1,288,558 ) $ 913,490 Vesting of restricted common stock 72,040 1 ( 1 ) — — — Stock-based compensation — — 31,604 — — 31,604 Exercise of common stock options 33,343 — 240 — — 240 Other comprehensive income (loss) — — — ( 189 ) — ( 189 ) Net loss — — — — ( 91,051 ) ( 91,051 ) Balance at June 30, 2024 82,386,210 $ 824 $ 2,233,989 $ ( 1,110 ) $ ( 1,379,609 ) $ 854,094 Purchase of common stock under ESPP 58,726 1 1,223 — — 1,224 Vesting of restricted common stock 82,739 1 ( 1 ) — — — Stock-based compensation — — 29,559 — — 29,559 Exercise of common stock options 31,208 — 239 — — 239 Other comprehensive income (loss) — — — 2,869 — 2,869 Net loss — — — — ( 96,668 ) ( 96,668 ) Balance at September 30, 2024 82,558,883 $ 826 $ 2,265,009 $ 1,759 $ ( 1,476,277 ) $ 791,317 3 Beam Therapeutics Inc. Condensed Consolidated Statements of Stockholders’ Equity - Continued ( Unaudited ) (in thousands, except share amounts) Common Stock Additional Paid-in Accumulated Other Comprehensive Accumulated Total Stockholders’ Shares Amount Capital Income (Loss) Deficit Equity Balance at December 31, 2024 83,633,069 $ 836 $ 2,298,661 $ 679 $ ( 1,566,631 ) $ 733,545 Purchase of common stock under ESPP 90,436 1 1,500 — — 1,501 Issuance of common stock and pre-funded warrants, net of issuance costs of $ 30.8  million 16,151,686 162 470,316 — — 470,478 Vesting of restricted common stock 607,196 6 ( 6 ) — — — Stock-based compensation — — 26,682 — — 26,682 Exercise of common stock options 74,707 1 718 — — 719 Other comprehensive income (loss) — — — ( 519 ) — ( 519 ) Net loss — — — — ( 109,270 ) ( 109,270 ) Balance at March 31, 2025 100,557,094 $ 1,006 $ 2,797,871 $ 160 $ ( 1,675,901 ) $ 1,123,136 Issuance of common stock and pre-funded warrants, net of issuance costs of $ 30.8  million — — ( 4 ) — — ( 4 ) Vesting of restricted common stock 81,163 1 ( 1 ) — — — Stock-based compensation — — 24,367 — — 24,367 Exercise of common stock options 120,491 1 1,754 — — 1,755 Other comprehensive income (loss) — — — ( 150 ) — ( 150 ) Net loss — — — — ( 102,291 ) ( 102,291 ) Balance at June 30, 2025 100,758,748 $ 1,008 $ 2,823,987 $ 10 $ ( 1,778,192 ) $ 1,046,813 Purchase of common stock under ESPP 84,272 1 1,262 — — 1,263 Vesting of restricted common stock 95,580 1 ( 1 ) — — — Stock-based compensation — — 22,747 — — 22,747 Issuance of common stock for acquisition 403,128 4 6,711 — — 6,715 Exercise of common stock options 18,037 — 412 — — 412 Other comprehensive income (loss) — — — 780 — 780 Net loss — — — — ( 112,728 ) ( 112,728 ) Balance at September 30, 2025 101,359,765 $ 1,014 $ 2,855,118 $ 790 $ ( 1,890,920 ) $ 966,002 The accompanying notes are an integral part of these condensed consolidated financial statements. 4 Beam Therapeutics Inc. Condensed Consolidated Statem ents of Cash Flows ( Unaudited ) (in thousands) Nine Months Ended September 30, 2025 2024 Operating activities Net loss $ ( 324,289 ) $ ( 286,388 ) Adjustments to reconcile net loss to net cash provided by (used in) operating activities: Depreciation and amortization 16,626 16,482 Amortization of investment discount (premiums) ( 12,700 ) ( 18,125 ) In-process research and development charge 14,507 — Stock-based compensation expense 73,796 90,444 Change in operating lease right-of-use assets 7,870 7,193 Change in fair value of derivative liabilities ( 650 ) ( 2,400 ) Change in fair value of contingent consideration liabilities ( 945 ) ( 1,619 ) Change in fair value of non-controlling equity investments ( 7,271 ) 13,003 Realized loss (gain) on sale of marketable securities 399 — Changes in operating assets and liabilities: Prepaid expenses and other current assets 4,452 2,458 Accounts payable 4,846 2,357 Accrued expenses and other liabilities ( 6,613 ) ( 53,610 ) Operating lease liabilities ( 10,005 ) ( 9,676 ) Deferred revenue ( 21,597 ) ( 31,451 ) Other long-term liabilities ( 239 ) 451 Net cash provided by (used in) operating activities ( 261,813 ) ( 270,881 ) Investing activities Purchases of property and equipment ( 11,212 ) ( 5,976 ) Purchases of marketable securities ( 848,754 ) ( 486,439 ) Maturities of marketable securities 624,456 551,142 Proceeds from sale of marketable securities 5,743 — Cash paid for acquisition, net ( 78 ) — Net cash provided by (used in) investing activities ( 229,845 ) 58,727 Financing activities Proceeds from issuance of common shares and pre-funded warrants, net of issuance costs 470,513 — Proceeds from issuances of stock under ESPP 2,764 2,622 Repayment of equipment financings — ( 485 ) Proceeds from exercise of stock options 2,886 2,155 Net cash provided by (used in) financing activities 476,163 4,292 Net change in cash, cash equivalents and restricted cash ( 15,495 ) ( 207,862 ) Cash, cash equivalents and restricted cash—beginning of period 290,111 444,614 Cash, cash equivalents and restricted cash—end of period $ 274,616 $ 236,752 The accompanying notes are an integral part of these condensed consolidated financial statements. 5 Beam Therapeutics Inc. Condensed Consolidated Statements of Cash Flows - Continued ( Unaudited ) (in thousands) Nine Months Ended September 30, 2025 2024 Supplemental disclosure of cash flow information: Cash paid for interest $ — $ 32 Supplemental disclosure of noncash investing and financing activities: Property and equipment additions in accounts payable and accrued expenses $ 3,126 $ 451 Operating lease liabilities arising from obtaining right-of-use assets $ — $ ( 1,010 ) Contingent consideration liabilities assumed in acquisition $ 7,715 $ — Fair value of equity instruments issued in connection with acquisition $ 6,715 $ — The accompanying notes are an integral part of these condensed consolidated financial statements. 6 Beam Therapeutics Inc. Notes to Condensed Consolidated Financial Statements ( Unaudited ) 1. Nature of the business and basis of presentation Organization Beam Therapeutics Inc., which we refer to herein as the “Company” or “Beam,” is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. Beam’s vision is to provide life-long cures to patients suffering from genetic diseases. The Company was incorporated on January 25, 2017 as a Delaware corporation and began operations in July 2017. Its principal offices are in Cambridge, Massachusetts. Liquidity and capital resources Since its inception, the Company has devoted substantially all of its resources to building its base editing platform and advancing development of its portfolio of programs, establishing and protecting its intellectual property, conducting research and development activities, making arrangements to conduct manufacturing activities with contract manufacturing organizations, organizing and staffing the Company, establishing and maintaining internal manufacturing capabilities, conducting clinical trials, maintaining its facilities and new facility build-outs, business planning, raising capital and providing general and administrative support for these operations. The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry including, but not limited to, technical risks associated with the successful research, development and manufacturing of product candidates, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to secure additional capital to fund operations. Current and future programs will require significant research and development efforts, including extensive preclinical and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure. Even if the Company’s product development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales. In March 2025, the Company closed an underwritten public offering of 16,151,686 shares of common stock at a public offering price of $ 28.48 per share and pre-funded warrants to purchase 1,404,988 shares of common stock at a purchase price of $ 28.47 per pre-funded warrant for agg Item 1A. Risk Factors 38 Item 5. Other Information 42 Item 6. Exhibits 43 Signatures 44 PART I. FINANCI AL INFORMATION Item 1. Financial St atements (Unaudited) Beam Therapeutics Inc. Condensed Consolidated Ba lance Sheets ( Unaudited ) (in thousands, except share and per share amounts) September 30, 2025 December 31, 2024 Assets Current assets: Cash and cash equivalents $ 267,960 $ 281,967 Marketable securities 807,010 568,773 Prepaid expenses and other current assets 23,577 27,409 Total current assets 1,098,547 878,149 Property and equipment, net 108,290 111,412 Restricted cash 6,656 8,144 Operating lease right-of-use assets 96,995 104,865 Other assets 593 1,254 Total assets $ 1,311,081 $ 1,103,824 Liabilities and stockholders’ equity Current liabilities: Accounts payable $ 9,545 $ 3,871 Accrued expenses and other current liabilities 42,314 47,468 Current portion of derivative liabilities 6,500 8,400 Current portion of deferred revenue 110,320 108,858 Current portion of lease liability 12,688 13,469 Current portion of consideration liabilities 1,192 — Total current liabilities 182,559 182,066 Long-term lease liability 138,732 147,956 Long-term portion of contingent consideration liabilities 6,708 1,131 Long-term portion of deferred revenue 10,160 33,218 Long-term portion of derivative liabilities 6,654 5,404 Other liabilities 266 504 Total liabilities 345,079 370,279 Commitments and contingencies  (See Note 7, License agreements and Note 8,  Collaboration and license agreements ) Stockholders’ equity: Preferred stock, $ 0.01  par value; 25,000,000  shares authorized, and no  shares issued or outstanding at September 30, 2025 and December 31, 2024, respectively — — Common stock, $ 0.01  par value; 250,000,000  shares authorized, 101,359,765  and 83,633,069  issued and outstanding at September 30, 2025 and December 31, 2024, respectively 1,014 836 Additional paid-in capital 2,855,118 2,298,661 Accumulated other comprehensive (loss) income 790 679 Accumulated deficit ( 1,890,920 ) ( 1,566,631 ) Total stockholders’ equity 966,002 733,545 Total liabilities and stockholders’ equity $ 1,311,081 $ 1,103,824 The accompanying notes are an integral part of these condensed consolidated financial statements. 1 Beam Therapeutics Inc. Condensed Consolidated Statements of Operati ons and Other Comprehensive Loss ( Unaudited ) (in thousands, except share and per share amounts) Three Months Ended September 30, Nine Months Ended September 30, 2025 2024 2025 2024 License and collaboration revenue $ 9,698 $ 14,269 $ 25,634 $ 33,451 Operating expenses: Research and development 109,769 94,258 310,343 266,117 General and administrative 26,740 26,515 81,539 82,865 Total operating expenses 136,509 120,773 391,882 348,982 Loss from operations ( 126,811 ) ( 106,504 ) ( 366,248 ) ( 315,531 ) Other income (expense): Change in fair value of derivative liabilities ( 2,757 ) ( 200 ) 650 2,400 Change in fair value of non-controlling equity investments 4,937 ( 2,064 ) 7,271 ( 13,003 ) Change in fair value of contingent consideration liabilities 1,000 ( 27 ) 945 1,619 Interest and other income (expense), net 10,903 12,127 33,093 38,166 Total other income (expense) 14,083 9,836 41,959 29,182 Net loss before income taxes ( 112,728 ) ( 96,668 ) ( 324,289 ) ( 286,349 ) Provision for income taxes — — — ( 39 ) Net loss $ ( 112,728 ) $ ( 96,668 ) $ ( 324,289 ) $ ( 286,388 ) Unrealized gain (loss) on marketable securities 780 2,869 111 1,155 Comprehensive loss $ ( 111,948 ) $ ( 93,799 ) $ ( 324,178 ) $ ( 285,233 ) Net loss per common share, basic and diluted $ ( 1.10 ) $ ( 1.17 ) $ ( 3.32 ) $ ( 3.49 ) Weighted-average common shares outstanding, basic and diluted 102,570,801 82,410,095 97,567,229 82,141,383 The accompanying notes are an integral part of these condensed consolidated financial statements. 2 Beam Therapeutics Inc. Condensed Consolidated Statements of Stockholders’ Equity ( Unaudited ) (in thousands, except share amounts) Common Stock Additional Paid-in Accumulated Other Comprehensive Accumulated Total Stockholders’ Shares Amount Capital Income (Loss) Deficit Equity Balance at December 31, 2023 81,632,496 $ 816 $ 2,169,798 $ 604 $ ( 1,189,889 ) $ 981,329 Purchase of common stock under ESPP 76,461 1 1,397 — — 1,398 Vesting of restricted common stock 420,579 4 ( 4 ) — — — Stock-based compensation — — 29,281 — — 29,281 Exercise of common stock options 151,291 2 1,674 — — 1,676 Other comprehensive income (loss) — — — ( 1,525 ) — ( 1,525 ) Net loss — — — — ( 98,669 ) ( 98,669 ) Balance at March 31, 2024 82,280,827 $ 823 $ 2,202,146 $ ( 921 ) $ ( 1,288,558 ) $ 913,490 Vesting of restricted common stock 72,040 1 ( 1 ) — — — Stock-based compensation — — 31,604 — — 31,604 Exercise of common stock options 33,343 — 240 — — 240 Other comprehensive income (loss) — — — ( 189 ) — ( 189 ) Net loss — — — — ( 91,051 ) ( 91,051 ) Balance at June 30, 2024 82,386,210 $ 824 $ 2,233,989 $ ( 1,110 ) $ ( 1,379,609 ) $ 854,094 Purchase of common stock under ESPP 58,726 1 1,223 — — 1,224 Vesting of restricted common stock 82,739 1 ( 1 ) — — — Stock-based compensation — — 29,559 — — 29,559 Exercise of common stock options 31,208 — 239 — — 239 Other comprehensive income (loss) — — — 2,869 — 2,869 Net loss — — — — ( 96,668 ) ( 96,668 ) Balance at September 30, 2024 82,558,883 $ 826 $ 2,265,009 $ 1,759 $ ( 1,476,277 ) $ 791,317 3 Beam Therapeutics Inc. Condensed Consolidated Statements of Stockholders’ Equity - Continued ( Unaudited ) (in thousands, except share amounts) Common Stock Additional Paid-in Accumulated Other Comprehensive Accumulated Total Stockholders’ Shares Amount Capital Income (Loss) Deficit Equity Balance at December 31, 2024 83,633,069 $ 836 $ 2,298,661 $ 679 $ ( 1,566,631 ) $ 733,545 Purchase of common stock under ESPP 90,436 1 1,500 — — 1,501 Issuance of common stock and pre-funded warrants, net of issuance costs of $ 30.8  million 16,151,686 162 470,316 — — 470,478 Vesting of restricted common stock 607,196 6 ( 6 ) — — — Stock-based compensation — — 26,682 — — 26,682 Exercise of common stock options 74,707 1 718 — — 719 Other comprehensive income (loss) — — — ( 519 ) — ( 519 ) Net loss — — — — ( 109,270 ) ( 109,270 ) Balance at March 31, 2025 100,557,094 $ 1,006 $ 2,797,871 $ 160 $ ( 1,675,901 ) $ 1,123,136 Issuance of common stock and pre-funded warrants, net of issuance costs of $ 30.8  million — — ( 4 ) — — ( 4 ) Vesting of restricted common stock 81,163 1 ( 1 ) — — — Stock-based compensation — — 24,367 — — 24,367 Exercise of common stock options 120,491 1 1,754 — — 1,755 Other comprehensive income (loss) — — — ( 150 ) — ( 150 ) Net loss — — — — ( 102,291 ) ( 102,291 ) Balance at June 30, 2025 100,758,748 $ 1,008 $ 2,823,987 $ 10 $ ( 1,778,192 ) $ 1,046,813 Purchase of common stock under ESPP 84,272 1 1,262 — — 1,263 Vesting of restricted common stock 95,580 1 ( 1 ) — — — Stock-based compensation — — 22,747 — — 22,747 Issuance of common stock for acquisition 403,128 4 6,711 — — 6,715 Exercise of common stock options 18,037 — 412 — — 412 Other comprehensive income (loss) — — — 780 — 780 Net loss — — — — ( 112,728 ) ( 112,728 ) Balance at September 30, 2025 101,359,765 $ 1,014 $ 2,855,118 $ 790 $ ( 1,890,920 ) $ 966,002 The accompanying notes are an integral part of these condensed consolidated financial stateme results of operations; • our expectations regarding the initiation, timing, progress and results of our clinical trials, including our Phase 1/2 clinical trial designed to assess the safety and efficacy of BEAM-101 for the treatment of sickle cell disease, our Phase 1/2 clinical trial designed to assess the safety and efficacy of BEAM-302 for the treatment of alpha-1 antitrypsin deficiency, our Phase 1/2 clinical trial designed to assess the safety and efficacy of BEAM-301 for the treatment of glycogen storage disease type 1a, and our Phase 1 healthy volunteer clinical trial of BEAM-103; • our expectations regarding the initiation, timing, progress and results of our research and development programs and preclinical studies; • our ability to develop and maintain a sustainable portfolio of product candidates; • our ability to develop life-long, curative, precision genetic medicines for patients through base editing; • our ability to create a hub for partnering with other companies; • our plans for preclinical studies for product candidates in our pipeline; • our ability to advance any product candidates that we may develop and successfully complete any clinical trials or preclinical studies, including the manufacture of any such product candidates; • our ability to pursue a broad suite of clinically validated delivery modalities; • our expectations regarding our ability to generate additional novel lipid nanoparticles that we believe could accelerate novel nonviral delivery of gene editing or other nucleic acid payloads to tissues beyond the liver and our ability to expand the reach of our programs; • the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and technology; • developments related to our competitors and our industry; • the expected timing, progress and success of our collaborations with third parties, including any future payments we may receive under our collaboration and license agreements, and our ability to identify and enter into future license agreements and collaborations; • developments related to base editing technologies; • our ability to successfully develop our delivery modalities and obtain and maintain approval for our product candidates; • our ability to successfully maintain a commercial-scale current Good Manufacturing Practice, or cGMP, manufacturing facility; • regulatory developments in the United States and foreign countries; • our ability to attract and retain key scientific and management personnel; • our expectations regarding the strategic and other potential benefits of our acquisition of any additional technologies, as well as the potential of contingent payments in connection with such acquisitions; • our estimates regarding the period over which we believe that our existing cash, cash equivalents and marketable securities, will be sufficient to fund our operating expenses and capital expenditure requirements; and • the impact on our business of macro-economic conditions, as well as the prevailing level of macro-economic, business, and operational uncertainty, including as a result of geopolitical events, federal government shutdowns, the imposition of new or revised global trade tariffs or other global or regional events. All of these statements are subject to known and unknown important risks, uncertainties and other factors that may cause our actual results, performance or achievements, market trends, or industry results to differ materially from those expressed or implied by such forward-looking statements. Therefore, any statements contained herein that are not statements of historical fact may be forward-looking statements and should be evaluated as such. Without limiting the foregoing, the words “anticipate,” “expect,” “suggest,” “plan,” “believe,” “intend,” “project,” “forecast,” “estimates,” “targets,” “projections,” “should,” “could,” “would,” “may,” “might,” “will,” and the negative thereof and similar words and expressions are intended to identify forward-looking statements. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including those described in “Risk Factors” in Part II, Item 1A of this Quarterly Report on Form 10-Q and “Risk Factors Summary” and “Risk Factors” in Part I, Item 1A. of our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, or the 2024 Form 10-K. Unless legally required, we assume no obligation to update any such forward-looking information to reflect actual results or changes in the factors affecting such forward-looking information. When we use the terms “Beam,” the “Company,” “we,” “us” or “our” in this Quarterly Report on Form 10-Q, we mean Beam Therapeutics Inc. and its subsidiaries on a consolidated basis, unless the context indicates otherwise. Table of Contents Page PART I Financial Information Item 1. Financial Statements (Unaudited) 1 Condensed Consolidated Balance Sh

The provided excerpt is only the Form 10‑Q cover page for GE Vernova Inc. (GEV) for quarter ended 2026‑06‑30, with no financial statements, MD&A, segment results, guidance, backlog, risks, or other performance details included. As-is, it contains almost no trade-relevant incremental information beyond confirming the filing/period and listing details.

This excerpt is only the cover page/header of Sleep Number’s Form 10-Q for the quarter ended April 4, 2026. It contains filing metadata (issuer, ticker, exchange, address) but no financial statements, MD&A, guidance, risks, or operational commentary. As a result, it is not directly actionable for trading beyond confirming the filing exists.

The provided excerpt is only the cover/filing header of SoundHound AI, Inc.’s 10‑Q for the quarter ended 2026‑03‑31. It contains listing/security identifiers (SOUN, SOUNW) but no financial statements, MD&A, guidance, risk updates, liquidity details, or material events. As a result, there is insufficient information to form high-confidence, actionable bullish/bearish theses beyond generic “company filed its 10‑Q” metadata.

The provided excerpt is only the boilerplate cover/filing-status section of Teucrium Commodity Trust’s Form 10‑Q for period ended 2026‑03‑31, with no portfolio holdings, performance, risk, or material updates included. As-is, it contains no actionable investment information beyond confirming the existence of the filing and the issuer/ticker identity (WEAT).

The provided text is only the cover/header portion of Archer Aviation’s Form 10‑Q for the quarter ended 2026‑03‑31 (issuer identity, exchange listing, and securities outstanding). It contains no operating/financial results, guidance, liquidity details, backlog, or risk-factor updates—so it is minimally actionable for trading beyond basic security identifiers and a generic dilution/optionality consideration from warrants.

This excerpt is essentially the cover page of CleanSpark, Inc.’s Form 10-Q for the quarter ended March 31, 2026. It contains identifiers (CIK/file no.), listing venue, and security descriptions (common stock and redeemable warrants with specific exercise terms), but no operating/financial results, guidance, risks, or MD&A detail. Actionability is therefore limited to capital-structure/dilution considerations around the listed warrant.

This excerpt of AST SpaceMobile’s 10‑Q is largely SEC cover-page/boilerplate (registrant info, exchange listing, filing compliance) and contains no financial results, guidance, liquidity, risk-factor updates, or operating metrics. As provided, it does not create a clear tradable catalyst beyond confirming continued reporting/listing status.

This excerpt only includes the cover page of Super Micro Computer, Inc.’s Form 10‑Q for the quarter ended March 31, 2026. It confirms the filing, issuer identity, listing (Nasdaq), and ticker (SMCI), but contains no financial results, guidance, risks, or MD&A content to support a directional investment view.